Surgery: Future directions in multimodality therapy for NSCLC.
Patients with stage III non-small-cell lung cancer (nSclc) comprise a heterogeneous population; the role of surgical resection in this setting has been controversial. Albain and colleagues recently demonstrated that trimodality therapy with lobectomy had clinical benefit for patients with pathologic nodal N2 stage III nSclc. we discuss the trial and its implications for future lung cancer therapy.